Show simple item record

dc.contributor.authorAsghar, K
dc.contributor.authorAshiq, MT
dc.contributor.authorZulfiqar, B
dc.contributor.authorMahroo, A
dc.contributor.authorNasir, K
dc.contributor.authorMurad, S
dc.date.accessioned2021-10-19T01:51:54Z
dc.date.available2021-10-19T01:51:54Z
dc.date.issued2015
dc.identifier.issn1792-0981
dc.identifier.doi10.3892/etm.2014.2146
dc.identifier.urihttp://hdl.handle.net/10072/409249
dc.description.abstractIndoleamine 2,3‑dioxygenase (IDO) is an immunoregulatory enzyme. It plays a key role in various malignancies, infection and autoimmune diseases. IDO induces immunosuppression through the depletion of tryptophan and its downstream metabolites. Hepatitis C virus (HCV) has infected more than 12 million individuals in Pakistan. The aim of the present study was to assess the expression and activity of IDO in HCV‑infected patients. The functional enzymatic activity of IDO was measured by colorimetric assay. Serum samples from 100 HCV‑infected patients were taken to examine IDO activity and samples from 100 healthy volunteers were used as controls. Liver sections from patients with HCV (n=35) and healthy controls (n=5) were used for immunohistochemical studies. Immunohistochemical analysis revealed that IDO was overexpressed in 28 of 35 (80%) cirrhotic liver samples, whereas 5 of 35 (14.2%) cases presented moderate and 2 of 35 (5.7%) cases presented mild expression of IDO. The enzymatic activity of IDO was significantly higher in the serum samples of HCV‑infected patients as compared with those in the control. These data indicate that the expression of IDO correlated with the pathogenesis of disease. In summary, it is suggested that the high expression of IDO in the progressively cirrhotic livers of HCV‑infected patients might contribute to the development of hepatocellular carcinoma. IDO may characterize a novel therapeutic target against HCV.
dc.description.peerreviewedYes
dc.languageen
dc.publisherSpandidos Publications
dc.relation.ispartofpagefrom901
dc.relation.ispartofpageto904
dc.relation.ispartofissue3
dc.relation.ispartofjournalExperimental and Therapeutic Medicine
dc.relation.ispartofvolume9
dc.subject.fieldofresearchTraditional, complementary and integrative medicine
dc.subject.fieldofresearchNutrition and dietetics
dc.subject.fieldofresearchcode4208
dc.subject.fieldofresearchcode3210
dc.titleIndoleamine 2,3‑dioxygenase expression and activity in patients with hepatitis C virus‑induced liver cirrhosis
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationAsghar, K; Ashiq, MT; Zulfiqar, B; Mahroo, A; Nasir, K; Murad, S, Indoleamine 2,3‑dioxygenase expression and activity in patients with hepatitis C virus‑induced liver cirrhosis, Experimental and Therapeutic Medicine, 2015, 9 (3), pp. 901-904
dc.date.updated2021-10-13T06:26:48Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© 2015 Spandidos Publications. The attached file is reproduced here in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version.
gro.hasfulltextFull Text
gro.griffith.authorZulfiqar, Bilal


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record